-56%

est. 2Y upside i

HealthcareSeries A

Autoimmune conditions are rising faster than any other disease, now affecting over 50 million Americans. Yet they remain misunderstood, underdiagnosed, and overlooked. WellTheory is here to change that with a new kind of care that’s personalized, rooted in science, powered by AI, and delivered with compassion. We help people reduce symptoms, feel better, and live fuller lives — while helping employers and payors reduce their spend.

Rank

#236

Sector

Digital Health

Est. Liquidity

~4Y

Data Quality

Data: Medium

WellTheory presents a high-risk, high-reward equity opportunity.

Last updated: March 10, 2026

Bull (35%)+400%

WellTheory capitalizes on its specialized AI tools and expands B2B partnerships with employers and health plans, driving revenue to $23M by 2028. This strong performance in a growing $160B+ autoimmune market justifies a 15x revenue multiple, pushing valuation to $345M.

Base (30%)+109%

WellTheory maintains solid growth in its niche, expanding its D2C and B2B channels to reach $14.4M in revenue by 2028. Facing increasing competition, it achieves a 10x revenue multiple, resulting in a $144M valuation.

Bear (35%)-100%

Growth significantly decelerates due to increased incumbent competition from large telehealth players like Teladoc Health entering the autoimmune space, or slower-than-expected B2B adoption. Revenue stalls at $7M, leading to a down round and a valuation of $13.8M, wiping out common stock value due to $26.2M in liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Investors hold $26.2M in liquidation preferences, meaning common shareholders would receive nothing in an exit below this amount.

Dilution Risk

high

As a Series A company, WellTheory will likely undergo additional funding rounds (Series B, C) within the next 2 years, leading to further dilution of common stock.

Secondary Liquidity

none

There are no active secondary markets or tender offers for WellTheory's private shares at this early stage.

Questions to Ask at the Interview

Strategic questions based on WellTheory's data — designed to show you've done your homework.

  • 1

    “WellTheory's competitive moat is described as moderate, leveraging specialized AI and integrated care for autoimmune conditions. How is the team thinking about defending and strengthening this moat against larger telehealth incumbents like Teladoc Health, especially if they decide to build out more specialized autoimmune programs?”

  • 2

    “With 5x revenue growth in the past year and an estimated current revenue of $4.8M, what are the key drivers for sustaining this rapid growth, particularly as you scale your B2B partnerships with employers and health plans, and what are the revenue targets for the next 24 months?”

  • 3

    “Given the Series A funding and the significant liquidation preferences from investors, what is the company's long-term strategy for achieving a liquidity event that provides meaningful returns for common stock holders, and what is the anticipated timeline for such an event?”

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.